Andere talen Pieris Pharmaceuticals, Inc.

Aandelen

PIRS

US7207952026

Beurs gesloten - Nasdaq Andere beurzen 22:30:00 24-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
11,93 ^USD	-0,58%		-5,08%	-18,06%

29/03	Pieris Pharmaceuticals, Inc. rapporteert resultaten voor het volledige jaar dat eindigde op 31 december 2023	CI
05/01	Prime Medicine benoemt de CFO van Foghorn Therapeutics als nieuwe financieel directeur	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Pieris Pharmaceuticals Announces 1-for-80 Reverse Stock Split	22/04
Pieris Pharmaceuticals Shares Fall After 1-for-80 Reverse Stock Split Announcement	19/04
Pieris Pharmaceuticals : Announces 1-for-80 Reverse Stock Split - Form 8-K	18/04
North American Morning Briefing : Powell Awaited -2-	03/04
Pieris Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/03
Pieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty Potential	28/03
Pieris Pharmaceuticals : Announces Strategy to Maximize Partnered Milestone and Royalty Potential - Form 8-K	27/03
North American Morning Briefing : Stocks Edge -2-	27/03
Prime Medicine Names Foghorn Therapeutics' CFO to be its New Finance Chief	05/01
North American Morning Briefing : Stocks Seen -2-	15/11
Pieris Pharmaceuticals: Q3 Earnings Snapshot	14/11
Pieris Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
North American Morning Briefing : Stock Futures -2-	08/11
Pieris Pharmaceuticals, Inc.(NasdaqCM:PIRS) dropped from S&P Global BMI Index	18-09-23
Vicore Pharma's New CEO to Formally Take Office	08-09-23
Dr. Hitto Kaufmann appointed Chief Scientific Officer of Hansa Biopharma	04-09-23
Sweden’s Hansa Biopharma Appoints New Chief Scientific Officer	01-09-23
Dr. Hitto Kaufmann appointed Chief Scientific Officer of Hansa Biopharma	01-09-23
Pieris Pharmaceuticals Announces Milestone Achievement for Boston Pharmaceuticals Initiation of Phase 1/2 Study of BOS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific	18-08-23
Pieris Pharmaceuticals Says Patient Dosing in Cancer Drug Trial Triggers Milestone Payment From Boston Pharmaceuticals	17-08-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Pieris Pharmaceuticals, Inc.

Aandelen

PIRS

US7207952026

Andere talen

Filters